Andere talen Oncopeptides AB

Aandelen

ONCO

SE0009414576

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:59 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,955 ^SEK	+2,25%		-26,12%	-61,42%

15/04	Oncopeptides AB verzekert nationale terugbetaling voor Pepaxti in Spanje	CI
04/04	Oncopeptides AB (Publ) geeft verkoopprognose voor het eerste kwartaal van 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Oncopeptides publishes the 2023 Annual Report	22/04
Oncopeptides publishes prospectus relating to the rights issue	17/04
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)	15/04
Oncopeptides secures national reimbursement for Pepaxti in Spain	15/04
Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	15/04
Oncopeptides announces final terms for the fully guaranteed rights issue	08/04
Oncopeptides releases first quarter 2024 sales	04/04
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	04/04
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27/03
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27/03
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27/03
Extraordinary General Meeting in Oncopeptides AB (publ)	13/03
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	13/03
Oncopeptides : Oncopeptalks on the company's rights issue	13/03
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026	13/03
FDA Flexes Its New FDORA Muscles In Withdrawing An Accelerated Approval	08/03
Oncopeptides PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	04/03
Oncopeptides : to present at two investor events	04/03
Oncopeptides AB - Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	01/03
Oncopeptides' : PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	01/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Oncopeptides AB

Aandelen

ONCO

SE0009414576

Andere talen

Filters